960289-56-9

Usage

Uses

Used in Organic Synthesis:
Trans-3-dimethylamino-4-hydroxy-1-Boc-Pyrrolidine is used as a chiral building block for the synthesis of various biologically active compounds. Its unique structure allows for the creation of complex molecules with specific stereochemistry, which is crucial for the development of effective drugs.
Used in Pharmaceutical Chemistry:
trans-3-dimethylamino-4-hydroxy-1-Boc-Pyrrolidine is also used in pharmaceutical chemistry as a key intermediate in the synthesis of potential drug candidates. Its presence in the structure of these compounds can contribute to their pharmacological and medicinal properties, making it a valuable target for drug development and research.
Used in Asymmetric Catalysis:
Trans-3-dimethylamino-4-hydroxy-1-Boc-Pyrrolidine can act as a ligand in asymmetric catalysis, a field of chemistry that focuses on the selective synthesis of enantiomers, which are molecules that are mirror images of each other. This selective synthesis is important in the development of chiral drugs, where one enantiomer may have therapeutic effects while the other may be inactive or even harmful.
Used in Drug Development and Research:
Due to its potential pharmacological and medicinal properties, trans-3-dimethylamino-4-hydroxy-1-Boc-Pyrrolidine is a valuable target for drug development and research. Its unique structure and functional groups make it a promising candidate for the creation of new and effective therapeutic agents.

Upstream product

• 50-00-0 formaldehyd 
• 252574-03-1 (3S,4S)-1-tert-butoxycarbonyl-trans-3-benzylamino-4-hydroxypyrrolidine 
• 64-18-6 formic acid 
• 124-40-3 dimethyl amine 
• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 190792-74-6 (3S,4S)-4-amino-1-N-tert-butyloxycarbonyl-3-hydroxypyrrolidine 

Downstream Products

• 960289-61-6 (3S,4S)-4-(dimethylamino)pyrrolidin-3-ol 

Relevant academic research and scientific papers

QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS

The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

SPIROINDOLINONES AS DDR1 INHIBITORS

The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF

Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.

INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

NOVEL MCH RECEPTOR ANTAGONISTS

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.

AMIDE DERIVATIVE AND MEDICINE

The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula [1]: (wherein R1 represents -CH2-R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.